Skip to main content
Onconic Therapeutics Inc. logo

Onconic Therapeutics Inc. — Investor Relations & Filings

Ticker · 476060 ISIN · KR7476060009 KO Manufacturing
Open in API
Filings indexed 125 across all filing types
Latest filing 2025-10-13 Regulatory Filings
Country KR South Korea
Listing KO 476060

About Onconic Therapeutics Inc.

http://onconic.co.kr/

Onconic Therapeutics Inc., established in 2020, is a biopharmaceutical company specializing in the research and development of innovative drugs. A subsidiary of Jeil Pharmaceutical, the company focuses on creating novel treatments for cancer and gastrointestinal disorders, including gastroesophageal reflux disease. Its development strategy prioritizes therapeutics for conditions with high unmet medical needs and significant market potential. Onconic Therapeutics actively advances its pipeline of drug candidates through various stages of clinical trials.

Recent filings

Filing Released Lang Actions
주식매수선택권부여에관한신고
Regulatory Filings Classification · 95% confidence The document is a detailed disclosure regarding the granting of stock options (주식매수선택권 부여) by Onconic Therapeutics Co., Ltd. It includes specifics such as grant dates, exercise prices, number of shares, conditions, and adjustments due to stock splits and bonus issues. The document is addressed to regulatory bodies (Financial Services Commission/Korea Exchange) and contains detailed financial and contractual information about stock option grants to directors and employees. It is not an announcement of a report publication but a substantive regulatory disclosure about stock option grants. This fits the category of a Regulatory Filing (RNS) as it is a regulatory announcement that does not fit into other specific categories like capital changes or director dealings, since it is about stock option grants and related details. The document length is 4306 characters, which is relatively short but contains detailed data, so it is not a mere announcement but a regulatory filing. Therefore, the best classification is Regulatory Filings (RNS).
2025-10-13 Korean
주식매수선택권부여에관한신고
Regulatory Filings Classification · 95% confidence The document is a detailed disclosure regarding the granting of stock options (주식매수선택권 부여) by the company Onconic Therapeutics Co., Ltd. It includes specifics such as grant dates, exercise prices, number of shares, adjustment due to stock splits and bonus issues, and the rationale behind the grant. It is addressed to regulatory bodies (Financial Services Commission/Korea Exchange) and contains detailed financial and contractual information about the stock options granted to directors and employees. This type of document is a regulatory announcement related to insider transactions or share-based compensation but does not fit the categories of full financial reports, earnings releases, or management reports. It is not a report publication announcement since it contains substantive data, but it is primarily a regulatory disclosure about stock option grants. According to the filing definitions, this corresponds best to a Regulatory Filings (RNS) category, which is the fallback for miscellaneous regulatory announcements that do not fit other categories. The document is not about director's personal share transactions (DIRS) but about company stock option grants. Therefore, the classification is RNS with high confidence.
2025-10-13 Korean
기업설명회(IR)개최
Investor Presentation Classification · 95% confidence The document is an announcement of an upcoming investor presentation (IR) event scheduled for October 14, 2025. It includes details such as date, time, location, target audience, purpose, and contact information. The document does not contain actual financial statements or detailed financial analysis but rather information about the event where such information will be presented. Therefore, it fits the category of an Investor Presentation announcement rather than the presentation or report itself.
2025-10-13 Korean
권리락 (무상증자)
Share Issue/Capital Change Classification · 100% confidence The document is a short announcement about a rights adjustment (권리락) related to a stock event, specifically a bonus issue (무상증자) for the company Onconic Therapeutics. It includes details such as the stock type, code, base price, and the effective date of the rights adjustment. The document is very brief (248 characters) and does not contain any financial statements or detailed analysis. This fits the category of Share Issue/Capital Change announcements, which cover new share issues or capital changes like stock splits or bonus issues.
2025-10-02 Korean
투자판단관련주요경영사항(임상시험계획변경승인신청) (네수파립의 난소암 제2상 임상시험계획승인(변경승인)신청)
Regulatory Filings Classification · 95% confidence The document is a disclosure about a clinical trial plan change approval application related to a pharmaceutical company's drug development. It includes detailed information about the clinical trial phase, purpose, and regulatory submission date. The document is short (2023 characters) and serves as an announcement of a significant business event related to investment decisions, specifically the submission of an IND (Investigational New Drug) application to the Korean MFDS. It does not contain financial statements, audit information, or detailed financial results. It is not a full report but a regulatory announcement about a material event affecting investment decisions. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-10-01 Korean
투자판단관련주요경영사항(임상시험계획변경승인) (네수파립의 췌장암 제1b/2상 임상시험계획승인(변경승인))
Board/Management Information Classification · 95% confidence The document is a disclosure about a clinical trial plan change approval related to a pharmaceutical product. It includes details about the clinical trial phase, approval dates, regulatory body (MFDS), and investment cautionary notes. The document is short (2353 characters) and primarily serves as an announcement of a significant management event related to investment decisions, specifically the approval of a clinical trial plan change. It does not contain financial statements, audit information, or detailed financial analysis. It is not a full report like an Annual Report or Interim Report, nor is it a transcript or presentation. The content fits best under 'Management Information' related to key management decisions impacting investment judgment. Therefore, the appropriate classification is 'MANG' (Board/Management Information).
2025-09-29 Korean

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.